Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Copper Histidine in Menkes Disease and Copper Deficiency
NCT00811785Phase 3Completed
- Sponsor
- Cyprium Therapeutics, Inc.
- Start
- Feb 2009
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of copper histidine in Menkes disease, Occipital horn syndrome (OHS) and copper deficiency, sponsored by Cyprium Therapeutics, Inc. Primary endpoint: Neurological improvement in patients with OHS or unexplained copper deficiency at 3 years. Started Feb 2009; status: completed.
02
Drugs
copper histidine
03
Conditions
Menkes diseaseOccipital horn syndrome (OHS)copper deficiency
Beyond the preview
Go deeper on NCT00811785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00811785.